Fulzerasib plus cetuximab in first-line KRASG12C-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial

The Lancet Oncology 2026

View at publisher
Authors: Vanesa Gregorc, Margarita Majem, Giuseppe Lo Russo, M. Maio, Stephanie Salvagni, Vanesa Gutiérrez-Calderón, Maria Gonzalez-Cao, Sergio Sandiego Contreras, Anna Koumarianou, Alessandra Bearz, Reyes Bernabé-Caro, Santiago Francisco Ortiz Viteri
+13 more Miguel F. Sanmamed, Flora Zagouri, Teresa Morán Bueno, Chiara Lazzari, Sergio Martínez-Recio, A. Giménez-Capitán, Yue Zhang, Yue Shan, Huaqiang Zhu, Congqiao Zhao, Haige Shen, Yu Wang, Rafael Rosell
DOI: 10.1016/s1470-2045(25)00764-8
Cited by: 7
References: 29

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Lung Cancer Research Studies HER2/EGFR in Cancer Research

Publication details

Journal / source
The Lancet Oncology
Publisher
Elsevier BV
Volume
27
Issue
4
Pages
432–441
Publication date
31 March 2026
Language
EN